Results 91 to 100 of about 46,312 (227)
Therapeutic Advances in Neurological Disorders, 2014 Background: There are growing concerns for the side effects of dabigatran etexilate (dabigatran), including higher incidence of dyspepsia and gastrointestinal bleeding.
Georgios Tsivgoulis +15 more
doaj +1 more source
Vascular Health and Risk Management, 2013 Andreas Clemens,1 Mandy Fraessdorf,2 Jeffrey Friedman31Corporate Division Medicine, TA Cardiovascular, 2Medical Data Services, Boehringer Ingelheim GmbH & Co KG, Ingelheim am Rhein, Germany; 3Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT ...
Clemens A, Fraessdorf M, Friedman J
doaj
PLoS ONE, 2012 BackgroundDabigatran is associated with lower rate of stroke comparing to warfarin when anticoagulation control is sub-optimal. Genotype-guided warfarin dosing and management may improve patient-time in target range (TTR) and therefore affect the cost ...
Joyce H S You +3 more
doaj +1 more source
Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
Health and Quality of Life Outcomes, 2017 Background Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource ...
Shannon L. Reynolds +9 more
doaj +1 more source
Cleveland Clinic Journal of Medicine, 2012 Readers comment on the oral anticoagulant dabigatran (October 2011), and screening for cervical cancer (November 2011).
openaire +2 more sources
Medication Utilization Evaluation of Dabigatran and Rivaroxaban within a Large, Multicenter Health System. [PDF]
, 2013 Objective. The objective of this medication utilization evaluation (MUE) was to determine the appropriateness of dabigatran and rivaroxaban while also reviewing outcomes for safety and effectiveness within a large, multi-center health system. Methods.
Doolin, Meagan +4 more
core +1 more source
Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation:Contemporary findings in real-life Danish patients [PDF]
, 2017 Background The nonvitamin K antagonist oral anticoagulants have recently become available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on real‐life patient experience, including bleeding ...
Evans, David +8 more
core +3 more sources
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management [PDF]
, 2017 Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation ...
Cheung, KS, Leung, WK
core +1 more source
PLoS ONE, 2016 BackgroundDabigatran was proven to have similar effect on the prevention of recurrence of venous thromboembolism (VTE) and a lower risk of bleeding compared to vitamin K antagonists (VKA). The aim of this study is to assess the cost-effectiveness (CE) of
J Stevanović +5 more
doaj +1 more source
Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
Pharmaceuticals, 2012 Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients.
Josef Finsterer, Claudia Stöllberger
doaj +1 more source